Sevilla

• A Clinical Study to Evaluate the Effects of NXT007 Compared to Factor VIII Prophylaxis in People With Hemophilia A Recruiting
  2025-522434-32-00 5 2026-07-01 Hemophilia A Without Inhibitors
• A study to investigate the safety and efficacy of mRNA-3927 in participants with genetically confirmed propionic acidemia Recruiting
  2022-502910-10-00 7 2026-06-26 Propionic Acidemia
• Immunosuppressant Discontinuation in Elderly patients with ulcerative colitis And long-term remission Recruiting
  2025-524675-23-00 6 2026-06-24 Ulcerative Colitis
• DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t … Recruiting
  2025-520565-51-00 5 2026-06-23 small cell lung cancer
• Grass/Olive Immunotherapy for Rhinitis and Asthma (GOES) Recruiting
  2025-521709-42-00 5 2026-06-23 Allergic rhinoconjunctivitis with or without asthma due to clinically
• Grass Immunotherapy for Rhinitis and Asthma (GIRA) Recruiting
  2025-521736-10-00 5 2026-06-23 Allergic rhinoconjunctivitis with or without controlled asthma
• An Extension Study to Assess Long-Term Safety and Efficacy of Afimkibart in Participants with Rheumatoid Arthritis Recruiting
  2025-523579-47-00 4 2026-06-19 moderate to severe rheumatoid arthritis (RA)
• A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People with Hemophilia A Recruiting
  2025-522435-33-00 5 2026-06-17 Hemophilia A
• A clinical trial of MK-1084 and durvalumab in people with non-small cell lung cancer (MK-1084-015) Recruiting
  2025-522038-29-00 5 2026-06-16 Locally advanced, unresected (unresectable or medically inoperable or
• A clinical trial of V940 with or without MK-3475A in people with non-small cell lung cancer (V940-014) Recruiting
  2025-522643-18-00 5 2026-06-16 Stage I NSCLC
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Recruiting
  2025-523576-23-00 5 2026-06-12 Unresectable Stage III non-small cell lung cancer without progression
• Phase II/III randomized controlled open-label trial to evaluate the efficacy and safety of personalized tissue engineered veins in patients … Recruiting
  2025-524103-69-00 10 2026-06-10 Chronic Venous Insufficiency
• Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304) Recruiting
  2025-523495-23-00 5 2026-06-09 Resected Pancreatic Ductal Adenocarcinoma (PDAC)
• Phase III randomized international open label clinical trial of treatment Intensification with docetaxel plus apalutamide in patients with m … Recruiting
  2025-524408-30-01 5 2026-06-05 Metastatic hormone-sensitive prostate cancer
• Beamion 44: A study to test how well zongertinib is tolerated by people with advanced non-small cell lung cancer with HER2 mutations when gi … Recruiting
  2025-523567-38-00 4 2026-06-02 locally advanced or metastatic NSCLC
• Open-label Extension of KarXT + KarX-EC for Agitation in Alzheimer’s Disease Recruiting
  2024-519994-20-00 5 2026-06-01 Agitation Associated with Alzheimer’s Disease
• Study to Assess K1-70 in Participants with Active Thyroid Eye Disease Recruiting
  2024-519292-26-00 4 2026-05-28 Graves’ disease and active thyroid eye disease
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Recruiting
  2025-521590-13-00 5 2026-05-28 Moderately to Severely Active Crohn’s Disease
• An Efficacy and Safety Study of Clemizole HCl in Patients with Lennox-Gastaut Syndrome Recruiting
  2025-522552-20-00 5 2026-05-28 Lennox-Gastaut Syndrome
• A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease Recruiting
  2025-524001-33-00 4 2026-05-22 Graves’ Disease
• A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures Recruiting
  2025-524038-24-00 5 2026-05-22 Focal Epilepsy
• A study to investigate the long-term safety, tolerability and efficacy of balinatunfib in participants with Crohn’s disease or ulcerative co … Recruiting
  2025-522511-42-00 4 2026-05-19 Crohn's disease
• A Global Study Testing the New Drug Olverembatinib combined with chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Pos … Recruiting
  2024-511496-14-00 5 2026-05-14 Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic L
• An open-label extension (OLE) trial to evaluate long-term safety and tolerability of pelacarsen (TQJ230) Recruiting
  2024-519870-38-00 5 2026-05-11 Atherosclerotic cardiovascular disease (ASCVD)

Showing 97–120 of 1,638 trials